Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Vertex Pharmaceuticals (VRTX) stocks
Learn how to easily invest in Vertex Pharmaceuticals stocks.
Vertex Pharmaceuticals is a biotechnology business based in the US. Vertex Pharmaceuticals stocks (VRTX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $325.3 – a decrease of 2.72% over the previous week. Vertex Pharmaceuticals employs 4,800 staff and has a trailing 12-month revenue of around $9.2 billion.
How to buy Vertex Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – VRTX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
National Bank Direct Brokerage
- Commission-free trading
- Several account types available
- Access to array of research tools
CIBC Investor's Edge
- Easy to use platform
- Low fees
- Student and young investor discounts
- Access to international stock exchanges
- Low margin rates
- Powerful research tools
What's in this guide?
- Can I buy shares in Vertex Pharmaceuticals?
- Has coronavirus impacted Vertex Pharmaceuticals shares?
- Vertex Pharmaceuticals shares summary
- Compare share dealing platforms
- Is Vertex Pharmaceuticals stock a buy or sell?
- Vertex Pharmaceuticals performance over time
- Is Vertex Pharmaceuticals suitable for ethical investing?
- Are Vertex Pharmaceuticals shares over-valued?
- Vertex Pharmaceuticals's financials
- How volatile are Vertex Pharmaceuticals shares?
- Does Vertex Pharmaceuticals pay a dividend?
- Have Vertex Pharmaceuticals shares ever split?
- Other common questions
Vertex Pharmaceuticals stock price (NASDAQ:VRTX)Use our graph to track the performance of VRTX stocks over time.
Vertex Pharmaceuticals shares at a glance
|Latest market close||$323.57|
|52-week range||$243.17 - $354.46|
|50-day moving average||$329.16|
|200-day moving average||$306.32|
|Wall St. target price||$345.06|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$12.41|
Buy Vertex Pharmaceuticals stocks from these online trading platformsCompare special offers, low fees and a wide range of investment options among top trading platforms.
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Vertex Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Vertex Pharmaceuticals price performance over time
Historical closes compared with the close of $323.57 from 2023-05-31
|1 week (2023-05-25)||-2.72%|
|1 month (2023-05-01)||-6.21%|
|3 months (2023-03-01)||11.10%|
|6 months (2022-12-01)||0.88%|
|1 year (2022-05-28)||N/A|
|2 years (2021-06-01)||54.32%|
|3 years (2020-06-01)||12.88%|
|5 years (2018-06-01)||112.80%|
Is Vertex Pharmaceuticals stock undervalued or overvalued?
Valuing Vertex Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vertex Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Vertex Pharmaceuticals's P/E ratio
Vertex Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 27x. In other words, Vertex Pharmaceuticals shares trade at around 27x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Vertex Pharmaceuticals's PEG ratio
Vertex Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4128. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Vertex Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Vertex Pharmaceuticals's EBITDA
Vertex Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.6 billion.
The EBITDA is a measure of a Vertex Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Vertex Pharmaceuticals financials
|Revenue TTM||$9.2 billion|
|Operating margin TTM||48.51%|
|Gross profit TTM||$5.3 billion|
|Return on assets TTM||16.8%|
|Return on equity TTM||25.73%|
|Market capitalisation||$85.7 billion|
TTM: trailing 12 months
Vertex Pharmaceuticals's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Vertex Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Vertex Pharmaceuticals's total ESG risk score
Total ESG risk: 30.84
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Vertex Pharmaceuticals's overall score of 30.84 (as at 01/01/2019) is nothing to write home about – landing it in it in the 44th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Vertex Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Vertex Pharmaceuticals's environmental score
Environmental score: 5.65/100
Vertex Pharmaceuticals's environmental score of 5.65 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Vertex Pharmaceuticals's social score
Social score: 24.22/100
Vertex Pharmaceuticals's social score of 24.22 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Vertex Pharmaceuticals's governance score
Governance score: 12.46/100
Vertex Pharmaceuticals's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Vertex Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Vertex Pharmaceuticals's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Vertex Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Vertex Pharmaceuticals has, for the most part, managed to keep its nose clean.
Vertex Pharmaceuticals share dividends
We're not expecting Vertex Pharmaceuticals to pay a dividend over the next 12 months.
Have Vertex Pharmaceuticals's shares ever split?
Vertex Pharmaceuticals's shares were split on a 2:1 basis on 24 August 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Vertex Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Vertex Pharmaceuticals shares which in turn could have impacted Vertex Pharmaceuticals's share price.
Vertex Pharmaceuticals share price volatility
Over the last 12 months, Vertex Pharmaceuticals's shares have ranged in value from as little as $243.17 up to $354.46. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vertex Pharmaceuticals's is 0.4905. This would suggest that Vertex Pharmaceuticals's shares are less volatile than average (for this exchange).
Vertex Pharmaceuticals overview
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG. ; Moderna, Inc.
Stocks similar to Vertex Pharmaceuticals
Vertex Pharmaceuticals in the news
Got $1,000? 2 Amazing Growth Stocks That Could Help You Retire Richer
CRISPR Therapeutics: A Galaxy's Worth of Deep Value
Tech Roars Back As MSFT, ASML, AMAT, ORCL Lead Industry Charge
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing
How do ETFs work?
Your guide to how ETFs work and whether this type of investment is right for you.Read more…
Best stock app for beginners for 2023
The best stock trading app for beginners is easy to use and offers free trades.Read more…
How to read stock charts
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.Read more…
More guides on Finder
Best bad credit loans in PEI
Compare some of the best bad credit loans in PEI.
Your guide to the features, interest rates and fees to expect when you apply for a short-term loan with Credito.
5 apps like Bree in Canada
Pay for unexpected bills and avoid overdrafts when you sign up for apps like Bree.
Debt Relief Canada (reliefcanada.ca) review
Take a closer look at the debt relief solutions, features and fees of Debt Relief Canada.
Desjardins Online Brokerage (Disnat) review 2023
Learn more about Desjardins Online Brokerage (Disnat) to see if it’s the right broker for you.
Guide to finding the best prepaid card in Canada in June 2023
We show you the best prepaid credit cards in Canada, whether you’re looking for a prepaid card with no fees, cash back rewards, or travel perks, or more.
How to buy Sui (SUI) in Canada
This guide provides step-by-step instructions on how to buy Sui, lists some exchanges where you can get it and provides daily price data on (SUI).
5 apps like Nyble in Canada
Compare apps like Nyble in Canada to access emergency funding.
Your guide to buying and financing a car in Canada with RightRide.
Compare bad credit car loans in BC
Your guide to bad credit car loans in BC and how to find the right financing for your needs.